Tag: Afrezza

Image Source: MannKind Corporation (Screenshot)

MannKind Corporation Skyrockets On Sanofi Agreement

MannKind shares surged 33.12% to $0.620 on Thursday after the company announced a settlement agreement with French drugmaker Sanofi. The biotech company said that Sanofi’s affiliate Aventisub has agreed to terminate the promissory note and security agreement with MannKind. Aventisub […]

MannKind Corporation Working To Take On Mylan’s EpiPen

MannKind Corporation Working To Take On Mylan’s EpiPen

MannKind is in the early stages of developing an inhalable form of epinephrine, which could help it take market share from the injectable version. Currently, injectable epinephrine is at the center of a storm over drug pricing, according to the LA Times. Previously, […]

MannKind Corporation Sinks On Poor Q1 Results

MannKind Corporation Sinks On Poor Q1 Results

MannKind shares tumbled 18.18% to $1.08 in pre-market trading Tuesday after the company released disappointing Q1 results on Monday. The Valencia-based company reported a net loss of 6 cents per share, worse than the Wall Street projections of 4 cents […]

MannKind Corporation Stock Soars, But Why?

MannKind Corporation Stock Soars, But Why?

Shares in biopharmaceutical company MannKind Corporation were up more than 20% at 10:30 am ET. The company announced a special conference call with investors in which it would reveal more about plans to commercialize Afrezza (insulin human) inhalation powder. MannKind […]

MannKind Corporation Tumbles After Q4 Results

MannKind Corporation Tumbles After Q4 Results

MannKind shares plunged 7.19% to $1.29 in after-hours trading Monday after the company released its fiscal fourth-quarter and full-year 2015 results. The biopharmaceutical company reported a net Q4 loss of 66 cents per share compared to a loss of just […]

MannKind Corporation (MNKD) In Trouble after SNY Gives Up

MannKind Corporation (MNKD) In Trouble after SNY Gives Up

To say that sales of biotech MannKind’s inhaled insulin powder Afrezza have been poor is a major understatement. That’s why it’s not too surprising that pharma major Sanofi has terminated it’s licensing agreement with MannKind for Afrezza. The firms announced […]